Physician profile

James Maxwell Feldman

Cardiovascular Disease · Houston, TX

NPI 1306860457

$21,322.22

in general payments reported to CMS, 2019-2025

43 companies · $840 in 2025

The $840 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,189.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ge Healthcare $10,200.00 2022
Abbott Laboratories $3,020.46 2019-2025 Jot Dx, Aveir, Mitraclip
Boston Scientific Corporation $2,324.60 2019-2025 Comet, Watchman Flx
Janssen Pharmaceuticals, INC $1,203.68 2019-2023 Xarelto
Novartis Pharmaceuticals Corporation $639.45 2019-2025
Amgen INC. $456.71 2019-2025 Repatha, Repatha
Edwards Lifesciences Corporation $400.47 2019-2025
Medtronic, INC. $385.40 2023-2025 Micra, Linq II
Abiomed $358.39 2022-2024 Impella
E.R. Squibb & Sons, L.L.C. $268.37 2019-2025 Camzyos, Eliquis
Biotronik INC. $198.07 2019-2022
Impulse Dynamics (USA) INC. $195.52 2022
Merck Sharp & Dohme LLC $190.39 2022-2025 Verquvo
Amarin Pharma, INC. $148.19 2019-2020
Melinta Therapeutics, LLC $122.07 2019
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $120.65 2022-2025
Philips North America LLC $111.98 2024 (Bh4) Igt Devices Undivided
Abbvie INC. $103.88 2022
Medtronic Vascular, INC. $93.75 2019-2020
Esperion Therapeutics, INC. $92.08 2021-2025 Nexletol
Sanofi-Aventis U.S. LLC $74.98 2019-2023
Astrazeneca Pharmaceuticals LP $69.74 2019-2021
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $69.53 2019-2024 Lifevest
Regeneron Healthcare Solutions, INC. $59.50 2019
Novo Nordisk INC $55.18 2024-2025 Wegovy, Rybelsus, Ozempic
Inspire Medical Systems, INC. $48.44 2023-2025 Inspire
Bard Peripheral Vascular, INC. $45.18 2025 Venclose Maven Catheter
Cardiva Medical, INC. $41.67 2022
Stryker Corporation $41.29 2025 Limflow System
Kiniksa Pharmaceuticals International, Plc $41.19 2024 Arcalyst
Tactile Systems Technology INC $39.77 2025 Nimbl, Flexitouch Plus
Boehringer Ingelheim Pharmaceuticals, INC. $33.35 2022-2023 Jardiance
Kiniksa Pharmaceuticals, LTD. $17.27 2023 Arcalyst
Lexicon Pharmaceuticals, INC. $13.92 2024
Cvrx, INC. $13.91 2024 Barostim Neo System
Preventice Services, LLC $12.21 2021
Kowa Pharmaceuticals America, INC. $10.98 2019

6 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$48.68 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Maxwell Feldman

$21,322.22

in general payments reported 2019-2025

Years
2019-2025
Top company
Ge Healthcare
Context
The $840 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/240295/james-maxwell-feldman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.